Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

NCT00118235 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: cisplatin
DRUG: irinotecan hydrochloride
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)